KR20230088718A - 항종양 아스코르브산 에스테르 - Google Patents

항종양 아스코르브산 에스테르 Download PDF

Info

Publication number
KR20230088718A
KR20230088718A KR1020237012737A KR20237012737A KR20230088718A KR 20230088718 A KR20230088718 A KR 20230088718A KR 1020237012737 A KR1020237012737 A KR 1020237012737A KR 20237012737 A KR20237012737 A KR 20237012737A KR 20230088718 A KR20230088718 A KR 20230088718A
Authority
KR
South Korea
Prior art keywords
compound
esi
cancer
ethyl acetate
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237012737A
Other languages
English (en)
Korean (ko)
Inventor
테레사 로요 바르게스
야가마레 폴 디옵
마리아 제네로사 데 로스 안젤레스 고메즈 파치오스
휴고 산탈라 가르시아
파티마 가리도 페르난데스
구이도 쿠르즈
마리아 루비에스 로요
Original Assignee
시헤네리스 파르마코스메틱스 에스.엘레.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시헤네리스 파르마코스메틱스 에스.엘레. filed Critical 시헤네리스 파르마코스메틱스 에스.엘레.
Publication of KR20230088718A publication Critical patent/KR20230088718A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237012737A 2020-09-14 2021-09-13 항종양 아스코르브산 에스테르 Pending KR20230088718A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382804.1A EP3967684A1 (en) 2020-09-14 2020-09-14 Antitumoral ascorbic acid esters
EP20382804.1 2020-09-14
PCT/EP2021/075104 WO2022053679A1 (en) 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters

Publications (1)

Publication Number Publication Date
KR20230088718A true KR20230088718A (ko) 2023-06-20

Family

ID=72709280

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237012737A Pending KR20230088718A (ko) 2020-09-14 2021-09-13 항종양 아스코르브산 에스테르

Country Status (10)

Country Link
US (1) US20230278974A1 (https=)
EP (2) EP3967684A1 (https=)
JP (1) JP7805651B2 (https=)
KR (1) KR20230088718A (https=)
CN (1) CN116724028B (https=)
AU (1) AU2021339010A1 (https=)
CA (1) CA3191119A1 (https=)
ES (1) ES3006988T3 (https=)
MX (1) MX2023002970A (https=)
WO (1) WO2022053679A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4676461A1 (en) * 2023-03-09 2026-01-14 Mastery Biotech Co., Ltd. Conjugate compound comprising 13-cis-retinoic acid and ascorbic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2831395B2 (ja) * 1989-09-12 1998-12-02 ハリマ化成株式会社 アスコルビン酸エステル
JP3781877B2 (ja) * 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
CN101550119B (zh) 2009-05-11 2012-05-30 无锡宏瑞生物医药科技有限公司 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物
JP2016104708A (ja) 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
JP6588764B2 (ja) 2015-01-26 2019-10-09 章博 田井 抗腫瘍剤
CN106139151A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物
CA3031979A1 (en) * 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Also Published As

Publication number Publication date
CA3191119A1 (en) 2022-03-17
ES3006988T3 (en) 2025-03-19
JP7805651B2 (ja) 2026-01-26
EP4211123C0 (en) 2024-11-06
JP2023541840A (ja) 2023-10-04
CN116724028B (zh) 2025-07-08
WO2022053679A1 (en) 2022-03-17
US20230278974A1 (en) 2023-09-07
AU2021339010A1 (en) 2023-03-23
EP4211123A1 (en) 2023-07-19
CN116724028A (zh) 2023-09-08
EP4211123B1 (en) 2024-11-06
EP3967684A1 (en) 2022-03-16
MX2023002970A (es) 2023-05-15

Similar Documents

Publication Publication Date Title
US11485726B2 (en) Compound for inhibiting and degrading tyrosine protein kinase ALK
US7781580B2 (en) Stilbene derivatives as new cancer therapeutic agents
US8916705B2 (en) Procaspase-activating compounds and compositions
US20140148400A1 (en) Carbonic anhydrase inhibitors with antimetastatic activity
KR20180105700A (ko) 체크포인트 키나아제 1(chk1) 억제제로서 유용한 3,5-이치환된 피라졸, 및 이의 제조 및 적용
CN112804995A (zh) 隐杯伞素类似物、其应用及其合成方法
US20210085640A1 (en) Acylated catechin polyphenols and methods of their use for the treatment of cancer
EP2924042A1 (en) Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof
KR20180134835A (ko) 5-아자사이티딘류의 당 부분(糖部) 실릴에테르 유도체
US9738613B2 (en) Substituted 1,2,3-triazoles as antitumor agents
EP2617714B1 (en) Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
KR20230088718A (ko) 항종양 아스코르브산 에스테르
EP3950677A1 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
US9115116B2 (en) Dual action inhibitors against histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase
AU2009279400A1 (en) Lipid compounds for supression of tumorigenesis
KR101495834B1 (ko) 신규한 1,2-디페닐에탄 유도체 및 이의 안드로겐 수용체 조절 효과
EP4635488A1 (en) Pharmaceutical composition for preventing or treating bone diseases
US12459910B2 (en) Mitochondrial therapeutic agents
US20240425515A1 (en) Compound of the 7a,8,9,10,11,11a-hexahydro-1h,7h-pyrano[2,3-c]xanthene type, method of preparation thereof, intermediates thereof and therapeutic applications thereof
EP1720849A1 (fr) Derives de pyranone utiles pour le traitement du cancer
KR102132960B1 (ko) 교모세포종의 예방 또는 치료용 신규 약학적 조성물
JP5034039B2 (ja) Ｇｍ３類似体
WO2010090234A1 (ja) 12-デオキシフシコクシン糖鎖改変誘導体およびその用途
WO2022040788A1 (en) Open-ring and lactone derivatives of unsaturated trihydroxy c-18 fatty acids and pharmaceutical compositions thereof having anti-cancer activity
JP2026510355A (ja) Ｇｐｒ３５モジュレーターとしての使用のための二環式ヘテロアリール化合物

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701